Glucagon-Like Peptide 1 Receptor (GLP-1R) Imaging for the Preoperative Localization of Benign Insulinomas in 30 Patients Abstract #477

Introduction: Biochemical diagnosis of endogenous hyperinsulinemic hypoglycemia is straightforward. Surgical removal of an insulinoma is hampered by difficulties to localize it using conventional radiological procedures. In vitro data suggest that human insulinoma cells exhibit a high density of GLP-1R. 111In-exendin-4 is an 111In labeled GLP-1R agonist that binds with high affinity to GLP-1R and may be helpful in localizing insulinomas.
Aim(s): To localize benign insulinomas using 111In-exendin-4 in patients with proven endogenous hyperinsulinemic hypoglycemia but no or one suspicious lesion on conventional imaging.
Materials and methods: 111In-exendin-4 was administered intravenously at a dose of (˜90 MBq) over five minutes to 30 patients (18 females, 12 males, age 53.5±14.9 years, mean±SD). Whole body planar images and SPECT/CT images of the abdomen were performed at 0.5h, 4h, 23h, 96h up to 168h post injection. Diagnosis was confirmed by histology after surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Emanuel Christ

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Antwi Antwi
#1057 Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study.
Introduction: SPECT/CT imaging with GLP1-R specific radiotracers like 111In-DOTA-exendin-4 have already proved to be a useful tool for the preoperative localisation of insulinomas. PET/CT has several advantages over SPECT/CT: lower radiation exposure, less time consumption and higher spatial resolution.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Christof Rottenburger
Authors: Rottenburger C, Antwi K, Heye T, Fani M, ...
#1802 Sensitivity of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI for the Localization of Benign Insulinomas: Interim Analysis of a Prospective Imaging Efficacy Study
Introduction: 40 patients (pat.) with positive whipple trias were enrolled (ClinicalTrials.gov, NCT02127541).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Antwi Antwi
Authors: Antwi A, Fani M, Heye T, Nicolas G, ...
Keywords: insulinoma, GLP-1R
#2003 Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study
Introduction: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults and due to their small size difficult to localise.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Antwi Antwi
Authors: Antwi A, Heye T, Fani M, Nicolas G, ...
#2984 AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy
Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
Authors: Grötzinger C, Exner S, Schuldt C, Du J, ...